Recent Updates
Recently added Catalysts
CRIS Neutral Sentiment

Hadassah Medical Center / Ein–Carem

Wednesday, October 23, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: Hadassah Medical Center and Ein-Carem are highlighted in the article, detailing their management structure, collaborations, and patient studies. The pipeline includes various treatments such as Emavusertib and Fimepinostat. The article also covers the company's investor relations and career opportunities.
Price reaction · baseline $109 (2024-10-22 close) · hit pre-market · 8 other CRIS headline(s) in the window, move may be shared
day 0 close · peak
-4.2%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~1 mo
High dilution risk
Lead asset
Emavusertib
Phase 2 · Chronic Lymphocytic Leukemia

Full Press Release Details

• About Company Overview Management Board of Directors Advisory Boards
• Collaborations Partner Collaborations Scientific & Research Collaborations
• Patients Patients Overview Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL Understanding Primary CNS Lymphoma Compassionate Use Policy
• Pipeline Pipeline Overview Emavusertib (CA-4948) Fimepinostat CA-170 CA-327
• Scientific Resources
• Investors Overview Press Releases Events and Presentations Corporate Governance Committee Composition Contact the Board Financial Information SEC Filings Annual Reports IRS Form 8937 Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage Contact Us
• Careers Life at Curis Open Positions Benefits
• Contact
• Company Overview
• Management
• Board of Directors
• Advisory Boards
• Partner Collaborations
• Scientific & Research Collaborations
• Patients Overview
• Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• Understanding Primary CNS Lymphoma
• Compassionate Use Policy
• Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• TakeAim Lymphoma
• TakeAim Leukemia
• TakeAim CLL
• Pipeline Overview
• Emavusertib (CA-4948)
• Fimepinostat
• CA-170
• CA-327
• Overview
• Press Releases
• Events and Presentations
• Corporate Governance Committee Composition Contact the Board
• Financial Information SEC Filings Annual Reports IRS Form 8937
• Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage
• Contact Us
• Committee Composition
• Contact the Board
• SEC Filings
• Annual Reports
• IRS Form 8937
• Interactive Chart
• Historical Stock Lookup
• Analyst Coverage
• Life at Curis
• Open Positions
• Benefits

Frequently Asked Questions

What is the focus of Hadassah Medical Center?

Hadassah Medical Center focuses on patient studies and collaborations in medical research.

What treatments are included in the pipeline?

The pipeline includes treatments like Emavusertib (CA-4948) and Fimepinostat.

What types of collaborations does the center have?

The center has partner collaborations and scientific research collaborations.

How can I learn about career opportunities at Curis?

Information about career opportunities at Curis can be found on their website.

ShareAdd on Google
Tags: CRIS Viatris Investor Conferences Healthcare Hadassah Medical Center Ein-Carem Emavusertib Fimepinostat
Last updated: Oct 23, 2024

Biotech snapshot

Cash runway
$5M liquidity · $3M/mo burn
~1 mo
High dilution risk
Lead asset
EmavusertibPhase 2
Chronic Lymphocytic Leukemia →